Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Molecular targets in salivary gland cancers: a comprehensive genomic analysis of 1,666 cases

Abirami Sivapiragasam, MD, Upstate Medical University, Syracuse, NY, provides an overview of a comprehensive genomic analysis of molecular targets in 1,666 cases of salivary gland cancers using the FoundationOne platform to assess molecular profiling. Patients with salivary duct carcinoma were observed to have the highest number of targetable treatment options. Approximately 32% of patients of these patients have PIKC3 alteration which can be considered for treatment with alpelisib. 60% of patients have HER2 amplification and 10% had high tumor mutational burden (TMB). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.